✦ LIBER ✦

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

✍ Scribed by Tsunekazu Kita; Yoshihiro Kikuchi; Masashi Takano; Mitsuaki Suzuki; Michitaka Oowada; Ryo Konno; Kenji Yamamoto; Hiromi Inoue; Hiroshi Seto; Tsutomu Yamamoto; Ken Shimizu

Book ID: 113959124
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 109 KB
Volume: 92
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2003.12.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

380 Phase I study with weekly Paclitaxel

380 Phase I study with weekly Paclitaxel (1 h) infusion in heavily pretreated advanced breast cancer and ovarian cancer patients

✍ U. Klaassen; H. Wilke; D. Strumberg; W. Eberhardt; M. Korn; S. Seeber 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Phase II study of single-agent gemcitabi

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

✍ Yoh Watanabe; Eiji Koike; Hidekatsu Nakai; Tomomaro Etoh; Hiroshi Hoshiai 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 237 KB

Phase II study of weekly topotecan in pa

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

✍ Tally Levy; Moshe Inbar; Joseph Menczer; Dan Grisaru; Marek Glezerman; Tamar Saf 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Phase I study with a weekly 1 h infusion

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer

✍ U. Klaassen; H. Wilke; D. Strumberg; W. Eberhardt; M. Korn; S. Seeber 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Pharmacokinetic study of weekly administ

Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

✍ Michiya Kobayashi; Koji Oba; Junichi Sakamoto; Ken Kondo; Naoki Nagata; Takehiro 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 182 KB

Response to letter to the editor in resp

Response to letter to the editor in response to “Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer”

✍ David M. O'Malley 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 123 KB